Nasdaq · CIK 0001563880
TRVI Trevi Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing 25 d ago. Close $13.19 on Oct 9, 2026, +36% from the 52-week low and -32% from the high.
Last 90 days
Net insider value
-$596k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$596k by 1 insider
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
TRVIOct 9, 2026 · close 13.19
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Trevi Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 19Weak | Michael Thomas Heffernan director sell | $596k 39,473 shares | -159% | - | |
| 16Weak | Jennifer L Good President & CEO sell | $35k 5,263 shares | -2% | - |
Transactions
The last 34 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | Michael Thomas Heffernan director | MOption exercise Common Stock10b5-1 | +18,421 | $3.04 | $56k | 24,772 | 25 d ago |
| Sep 15, 2026 | Michael Thomas Heffernan director | SOpen-market sale Common Stock10b5-1 | -18,321 | $15.09 | $276k | 6,451 | 25 d ago |
| Sep 15, 2026 | Michael Thomas Heffernan director | SOpen-market sale Common Stock10b5-1 | -100 | $15.88 | $1,588 | 6,351 | 25 d ago |
| Sep 15, 2026 | Michael Thomas Heffernan director | MOption exercise Common Stock10b5-1 | +21,052 | $3.33 | $70k | 27,403 | 25 d ago |
| Sep 15, 2026 | Michael Thomas Heffernan director | SOpen-market sale Common Stock10b5-1 | -20,952 | $15.09 | $316k | 6,451 | 25 d ago |
| Sep 15, 2026 | Michael Thomas Heffernan director | SOpen-market sale Common Stock10b5-1 | -100 | $15.88 | $1,588 | 6,351 | 25 d ago |
| Sep 15, 2026 | Michael Thomas Heffernan director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -18,421 | $0.00 | $0 | 0 | 25 d ago |
| Sep 15, 2026 | Michael Thomas Heffernan director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -21,052 | $0.00 | $0 | 0 | 25 d ago |
| Jun 11, 2025 | Dominick Colangelo director | AGrant or award Nonstatutory Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 13, 2025 |
| Jun 11, 2025 | Michael Thomas Heffernan director | AGrant or award Nonstatutory Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 13, 2025 |
| Jun 11, 2025 | Edward T Mathers director | AGrant or award Nonstatutory Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 13, 2025 |
| Jun 11, 2025 | David P Meeker director | AGrant or award Nonstatutory Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 13, 2025 |
| Jun 11, 2025 | Anne Vanlent director | AGrant or award Nonstatutory Stock Option (right to buy)derivative | +45,000 | $0.00 | $0 | 45,000 | Jun 13, 2025 |
| May 31, 2025 | Farrell Simon Chief Commercial Officer | AGrant or award Performance Stock Option (right to buy)derivative | +72,000 | $0.00 | $0 | 110,400 | Jun 3, 2025 |
| May 31, 2025 | Thomas Sciascia Chief Scientific Officer | AGrant or award Performance Stock Option (right to buy)derivative | +60,000 | $0.00 | $0 | 92,000 | Jun 3, 2025 |
| May 31, 2025 | Jennifer L Good President & CEO | AGrant or award Performance Stock Option (right to buy)derivative | +102,000 | $0.00 | $0 | 156,400 | Jun 3, 2025 |
| May 31, 2025 | Lisa Delfini Chief Financial Officer | AGrant or award Performance Stock Option (right to buy)derivative | +72,000 | $0.00 | $0 | 110,400 | Jun 3, 2025 |
| May 31, 2025 | Christopher Galletta See Remarks | AGrant or award Performance Stock Option (right to buy)derivative | +8,550 | $0.00 | $0 | 13,110 | Jun 3, 2025 |
| Mar 21, 2025 | Jennifer L Good President & CEO | MOption exercise Common Stock | +5,263 | $1.43 | $7,526 | 218,576 | Mar 25, 2025 |
| Mar 21, 2025 | Jennifer L Good President & CEO | SOpen-market sale Common Stock | -5,263 | $6.58 | $35k | 213,313 | Mar 25, 2025 |
| Mar 21, 2025 | Jennifer L Good President & CEO | MOption exercise Stock Option (right to buy)derivative | -5,263 | $0.00 | $0 | 0 | Mar 25, 2025 |
| Mar 10, 2025 | Lisa Delfini Chief Financial Officer | AGrant or award Performance Stock Option (right to buy)derivative | +38,400 | $0.00 | $0 | 38,400 | Mar 12, 2025 |
| Mar 10, 2025 | Jennifer L Good President & CEO | AGrant or award Performance Stock Option (right to buy)derivative | +54,400 | $0.00 | $0 | 54,400 | Mar 12, 2025 |
| Mar 10, 2025 | Christopher Galletta See Remarks | AGrant or award Performance Stock Option (right to buy)derivative | +4,560 | $0.00 | $0 | 4,560 | Mar 12, 2025 |
| Feb 18, 2025 | James Cassella V Chief Development Officer | AGrant or award Stock Option (right to buy)derivative | +257,500 | $0.00 | $0 | 257,500 | Feb 20, 2025 |
| Feb 18, 2025 | Christopher Galletta See Remarks | AGrant or award Stock Option (right to buy)derivative | +41,000 | $0.00 | $0 | 41,000 | Feb 20, 2025 |
| Feb 18, 2025 | Jennifer L Good President & CEO | AGrant or award Stock Option (right to buy)derivative | +811,000 | $0.00 | $0 | 811,000 | Feb 20, 2025 |
| Feb 18, 2025 | Lisa Delfini Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +225,500 | $0.00 | $0 | 225,500 | Feb 20, 2025 |
| Jan 7, 2025 | Lisa Delfini Chief Financial Officer | MOption exercise Common Stock | +1,000 | $0.51 | $511 | 59,660 | Jan 10, 2025 |
| Jan 8, 2025 | Lisa Delfini Chief Financial Officer | MOption exercise Common Stock | +5,000 | $0.51 | $2,555 | 64,660 | Jan 10, 2025 |
| Jan 7, 2025 | Lisa Delfini Chief Financial Officer | MOption exercise Stock Option (right to buy)derivative | -1,000 | $0.00 | $0 | 47,125 | Jan 10, 2025 |
| Jan 8, 2025 | Lisa Delfini Chief Financial Officer | MOption exercise Stock Option (right to buy)derivative | -5,000 | $0.00 | $0 | 42,125 | Jan 10, 2025 |
| Dec 13, 2024 | Christopher Galletta See Remarks | MOption exercise Common Stock | +15,000 | $0.51 | $7,665 | 19,935 | Dec 17, 2024 |
| Dec 13, 2024 | Christopher Galletta See Remarks | MOption exercise Stock Option (right to buy)derivative | -15,000 | $0.00 | $0 | 20,000 | Dec 17, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- James Cassella VChief Development Officer
- Dominick Colangeloceo, president, officer, director
- Lisa DelfiniChief Financial Officer
- Jennifer L GoodPresident & CEO
- Christopher GallettaSee Remarks
- Michael Thomas Heffernandirector
- Edward T Mathersdirector, owner
- David P Meekerceo, president, officer, director
- Thomas SciasciaChief Scientific Officer
- Farrell SimonChief Commercial Officer
- Anne Vanlentdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.